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Introduction: Thyroid cancer is the most common endocrine neoplasia and the papillary subtype is 
the most frequent; there are histological and clinical factors associated with a higher risk of recurrence 
and metastasis.
Objective: The aim of this study was to examine the histological, prognostic and clinical characteristics 
of papillary thyroid carcinomas diagnosed at the National Cancer Institute of Colombia.
Materials and methods: A retrospective cohort study was carried out on 619 patients with papillary 
thyroid carcinoma between 2006 and 2012; we analyzed the sociodemographic, histological, prognostic 
and clinical characteristics.
Results: 87.7% of cases were women. The presence of two or more variants in the same case was 
considered a particular variant, which we called combined pattern. Combined pattern was then the 
most frequent (50.9%), followed by the follicular variant (23.4%) including subtypes encapsulated and 
unencapsulated, and the classic variant (22.1%). Mean tumor size was 20.8 mm. More than half of the 
cases had capsular invasion, extrathyroidal invasion and lymph node involvement. When compared 
with the other variants, the combined pattern carcinomas had a higher risk of invasion of the thyroid 
capsule, extraganglionar invasion and metastasis.
Conclusions: Our results are in many aspects similar to those already reported. However, the presence 
of the combined pattern implied a higher risk for capsular invasion, nodal involvement, extranodal 
involvement and metastasis in comparison with those which had just one variant. Further studies are 
necessary to confirm these results.
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Variantes histológicas y factores pronósticos del carcinoma papilar de tiroides en el Instituto 
Nacional de Cancerología de Colombia, 2006-2012
Introducción. El cáncer de tiroides es la neoplasia más común y el subtipo papilar es el más frecuente; 
hay factores histológicos y clínicos asociados con un mayor riesgo de recidiva y metástasis.
Objetivo. Examinar las características histológicas, clínicas y de pronóstico de los carcinomas papilares 
de tiroides diagnosticados en el Instituto Nacional de Cancerología de Colombia.
Materiales y métodos. Se llevó a cabo un estudio de cohorte retrospectiva que incluyó a 619 
pacientes con carcinoma papilar de tiroides entre 2006 y 2012; se analizaron las características 
sociodemográficas, histológicas, de pronóstico y clínicas.
Resultados. El 87,7% de casos correspondió a mujeres. La presencia de dos o más variantes 
histológicas en un mismo caso se consideró como una variante a la cual se denominó patrón 
combinado; esta fue la más frecuente (50,9 %), seguida de la variante folicular (23,4 %), incluidos 
los subtipos encapsulados o no encapsulado y la variante clásica (22,1 %). El promedio del tamaño 
tumoral fue de 20,8 mm. En más de la mitad de los casos se evidenció invasión capsular, invasión 
extratiroidea y metástasis en ganglios linfáticos. Comparados con otras variantes histológicas, los 
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carcinomas con patrón combinado presentaron mayor riesgo de invasión de la cápsula tiroidea, de 
invasión extraganglionar y de metástasis.
Conclusión. En muchos aspectos los resultados fueron similares a los reportados previamente; 
sin embargo, se encontró que la presencia del patrón combinado aumentaba el riesgo de invasión 
capsular, metástasis en nódulos linfoides y extensión extratiroidea en comparación con los que tenían 
una sola variante. Sería necesario hacer estudios acerca del mecanismo biológico de la diferenciación 
en células cancerosas con el fin de ahondar sobre este fenómeno.
Palabras clave: glándula tiroides, neoplasias de la tiroides, carcinoma papilar, epidemiología. 
doi: http://dx.doi.org/10.7705/biomedica.v35i3.2598
Corresponding author:
Karime Osorio-Arango, Subdirección Nacional de Trasplantes 
y Bancos de Sangre, Dirección de Redes en Salud Pública, 
Instituto Nacional de Salud, Avenida calle 26 N° 51-20, Bogotá, 
D.C., Colombia
Telephone: (571) 220 7700, extension 1567
lkarime15@gmail.com
Recibido: 04/11/14; aceptado: 11/05/15
Thyroid cancer is the most frequent of all endocrine 
neoplasms (1). In Colombia it ranks eighth among 
all cancers with an incidence rate of 5.1 cases 
per 100,000 inhabitants (2,3). In general terms, its 
incidence has increased worldwide, a fact partially 
related to environmental risk, but also due to the 
availability of more sensitive diagnosis and tracking 
technology (1,4-6). Nowadays, small tumors are 
frequently detected and treated (7,8).
The World Health Organization (WHO) classifies 
malignant epithelial thyroid tumors into four major 
groups (papillary, follicular, medullary and undif-
ferentiated) (9). Papillary thyroid carcinoma (PTC) 
is the most common type, for about eight out of 
ten thyroid cancers belong to this histological 
type (1,4).
PTC is usually an indolent disease with a chronic 
course. The classic lesion appears as a proliferation 
of papillary structures lined by cells with eosino-
philic cytoplasm and enlarged nuclei, superimposed 
and with irregular contours. Some of these nuclei 
appear as optically empty or like frosted glass, 
which is made more evident in the cytological 
smears; they may have nuclear cleavage, and 
psammoma bodies can be found (1,9) They grow 
slowly, usually appear in only one thyroid lobe and 
often propagate to the neck lymph nodes (1,9).
Furthermore, PTC includes several histological 
variants which imply lesser or greater degrees 
of risk (6,10), and which are determined by size, 
specific growth and stromal reaction patterns; 
nonetheless, they also preserve specific papillary 
carcinoma nuclear characteristics (figure 1). 
Quantitative criteria to include a particular lesion 
in one of the variants are not universal (figure 1) 
(6,10-14). Not one of them includes a method for 
an objective measure of the amount of each variant 
contained into a lesion. The College of American 
Pathologists check list, widely used in the world, 
recommends mentioning the variants but gives no 
particular guide for quantification (15).
Cancer registries in Colombia are relatively new and 
fragmentary. The population-based cancer registry 
of Cali (Registro Poblacional de Cali, RPCC) collects 
information about the new cancer cases occurring in 
Colombia (16-18). Some studies about the disease 
have shown an increasing trend in the incidence of 
papillary carcinoma in women and a slight increase 
in men (17-19). However, the available information 
does not include detailed data about histological 
characteristics in Colombia (17,18). In order to 
shed light on the subject, we decided to describe 
the histological and clinical characteristics of the 
patients in a single institution.
Figure 1. Combined pattern. Most cases of papillary thyroid 
carcinoma are not a pure variant. Usually, a tumor is composed 
of at least two histological variants. We called the most extended 
pattern predominant subtype (A), and the next secondary 
subtypes (B). Hematoxylin eosin, 400X
A. Classic   B. Follicular   C. Solid variant   D. Tall cells
A
B
CD
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Materials and methods
We conducted a retrospective cohort study 
which included all patients diagnosed with PTC 
by the Grupo de Patología Oncológica at the 
Instituto Nacional de Cancerología, between 2006 
and 2012. A systematic and manual review of 
all pathology reports was carried out in order 
to ensure that no case would be omitted from 
the study. Then, all cases were confirmed and 
reclassified by the pathologist of the group, expert 
in diagnosing neuroendocrine disease; this allowed 
for the collection of data on histological variants and 
tumoral characteristics in accordance with WHO 
guidelines, the Classification of malignant tumors 
(TNM), the College of American Pathologists and 
local clinical guidelines (10,15,20,21).
Variant definition
As there is no universal consensus about the 
criteria for including a case in a particular PTC 
variant (1,9,13,21-27), and considering that the 
assessment of cell percentage is often subjective, 
we defined “combined pattern” as the presence 
of two or more histological variants in the same 
case. Each of the composing variants must be 
represented at least in 30% of tumoral cells. This 
combined pattern is made up of a predominant 
subtype, which corresponds to the histological 
variant with the greatest percentage of tumor 
cells, and of a secondary subtype, which relates 
to the subsequent histological variant with the next 
highest percentage of tumor cells.
Tumor characteristics included as variables of 
interest were: Thyroid capsule invasion, extrathyroid 
invasion, vascular invasion, lymph node and 
extranodal metastasis, tumor size and focality. We 
are aware of the discrepancy between pathologists 
concerning the existence of the thyroid capsule 
(28-30). However, we have included and used 
the term since our local guidelines include it, and 
because the concept is still important for a proper 
TNM classification (20,21,31). 
We followed the protocol of the College of American 
Pathologists for the evaluation of extrathyroid 
invasion (15,29-31).
Tumor size was categorized into three groups: 
1) Papillary microtumor (PMiT), i.e., those which: 
a) are unifocal of 10 mm or less, 
b) have no metastasis at the time of diagnosis; 
c) appear in adult patients; 
d) are multifocal and have a diameter that is still 
less than 10 mm; 
e) have no capsular or vascular invasion;
f) are of low risk from a histological stand point, and
g) were non-detectable through imaging (32,33). 
2) Microcarcinomas (PMC), i.e., tumors that measure 
10 mm or less and have any histological risk factor. 
Some authors report multifocality percentages 
ranging from 7% to 56%, a fact which increases 
recurrence and regional metastasis (5,31,32). In 
patients with multifocal microcarcinomas when the 
sum of the diameter of the lesions is greater than 
10 mm they are considered carcinomas. 
3) Carcinomas, i.e., tumors that measure over 10 
mm (30,31).
We defined relapse as the reappearance of the 
malignant tumor or tumor cells after a treatment. 
In order to discern relapse in this series a search 
was carried out through medical records using 
the SAP information system of medical records; 
the diagnosis made by the prescribing physician 
during checkups was taken into account as was 
the appearance of nodes or metastasis (local, loco-
regional or distant) following surgery.
Out of the 619 cases, relapse was analyzed in only 
211 given that they were the only cases for which 
the pathology departments had post-surgery follow-
up data. Age and gender were obtained from the 
medical charts. Age was categorized into groups 
according to the clinical interest: a) under 18 years 
of age, b) between 18 and 45 years of age and c) 
over 45 years of age. All data were included in an 
excel database (Microsoft Excel™). 
Statistical analysis
Initially, descriptive statistics were used to perform 
univariate analysis. Central tendency and dispersion 
were calculated for quantitative variables. For the 
remaining variables, calculations were made for 
absolute, relative and proportional frequencies 
using SPSS® 19.1 software.
Later, we performed an analysis of subgroups to 
observe how the principal histological variants 
and clinical characteristics behaved according 
to established gender and groups. The associ-
ation between tumor characteristics and major 
histological variants was explored in the bivariate 
analysis by calculating relative risks (RR) with their 
respective raw confidence intervals of 95% and 
taking as significant a value of p<0.05.
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Relapse was considered from the time of surgery 
to December, 2013.
Ethical considerations
This project was approved by the Board of Ethics 
of the Instituto Nacional de Cancerología.
Results
A total of 619 cases of papillary thyroid carcinoma 
were diagnosed at the Instituto Nacional de 
Cancerología from 2006 to 2012. Mean age at 
the time of diagnosis was 51 years (SD=13.95 
range 12-82) and most were women (87.7%). 
Other patient characteristics are shown in table 1. 
Population pyramid is shown in figure 2.
The most frequent histological variant was the 
combined pattern (50.9%), followed by the follicular 
variant (23.4%), the classic variant (22.1%), and in 
a lesser proportion, the cribriform, fasciitis nodular-
like, clear and squamous cell variants (0.2%) each.
Among patients who reported the combined pat-
tern, 90.6% included the predominant classic 
variant in their composition, followed by the 
follicular variant (4.18%); secondary subtypes 
included the follicular variant (90.9%) and the 
solid variant (2.89%).
Data on the histological characteristics of papillary 
thyroid carcinoma registered median tumor size of 
20.8 mm (SD=15.24, range: 1-89). Thyroid capsu-
lar invasion was present in 78.0% of the cases, 
extrathyroid invasion in 61.8%, lymphovascular 
invasion occurred in 29.5% and venous invasion in 
23.6%. Lymph node metastasis was encountered 
in 60.1% of cases and extranodal metastasis in 
36.5% (table 2).
Distribution by gender revealed that some histo-
logical variants occurred exclusively among women: 
clear cell, columnar cell, cribriform cell, diffuse 
sclerosis, fasciitis-like cell, macrofollicular cell and 
oncocytic cell variants. In contrast, the predominant 
histological variants in men were the classic (16.8%) 
and tall cell (9.1%) variants. The combined pattern 
occurred in an equal proportion of men and 
women. The histological variant analysis according 
to age group revealed that even though PTC may 
appear at any age, some variables show up more 
frequently in certain groups (table 2).
When histological variants were related to tumor 
size, it was observed that the combined pattern 
was present in most carcinomas (52.3%) and 
many microcarcinomas (44.1%), in contrast to 
microtumors, which characteristically had a greater 
percentage of the classic variant (40%).
We established a relationship between extrathyroid 
invasion and the type of histological variant since 
the former is a characteristic which determines 
tumoral behavior. Results showed a 19.3% and 
14% of extrathyroidal invasion for follicular and 
classic variants respectively, while the combined 
pattern displayed a 66.7%.
Table 1. Sociodemographic, clinical and pathological charac-
teristics of the patients with papillary thyroid carcinoma
Characteristics Frequency
n %
Gender (n=619)
Women
Men
Age (n=618)
<18 years old
18 to 45 years old
>45 years old
Type of lesion (n=398)
Multifocal
Unifocal
Largest tumor diameter (n=356)
0 to 10 mm
>10 mm
Tumor type (n=619)
Carcinoma
Microcarcinoma
Microtumor
Histological characteristics
Thyroid capsule invasion (n=559) 
Extrathyroid invasion (n=552)
Lymph node metastasis (n=446)
Extranodal metastasis (n=436)
Lymphovascular invasion (n=366)
Venous invasion (n=364)
543
  76
  11
219
388
220
178
114
242
546
  43
  30
436
341
268
159
108
  86
87.7
12.3
  1.8
35.4
62.8
55.3
44.7
32.0
68.0
88.2
  7.0
  4.8
78.0
61.8
60.1
36.5
29.5
23.6
Men
12 1211 1110 109 98 87 76 65 54 43 32 21 10 0
0-4
5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
%
Women85 and more
Figure 2. Population pyramid of the Colombian Instituto Nacional 
de Cancerología patients with papillary thyroid carcinoma 
from 2006 to 2012 
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The relapse analysis could only be performed on 
211 cases, 83.88% of which had shown no relapse 
from the time of surgery until the time of inclusion 
in the study. Among the patients who suffered 
relapse, 9.95% had loco-regional relapse; 4.26%, 
distant relapse, and 1.89%, local relapse.
The bivariate analysis of the most common variants 
and their histological characteristics showed that 
the classic variant has less chance of developing 
thyroid capsule invasion (RR=0.77, p=0.0001) 
and extrathyroid invasion (RR=0.67, p=0.0001); 
follicular variant presented RR less than 1 in all 
associations and the combined pattern showed a 
higher relative risk of 1 in all evaluated parameters 
(table 3).
Discussion
To date this is the first report on papillary thyroid 
carcinoma characteristics in Colombia. The distri-
bution of papillary thyroid carcinoma according 
to gender and age in our study is similar to that 
reported in universal literature (5), thus confirming 
that women of reproductive and middle age are the 
most affected. Among the men in our series the 
disease is rare, except among older men (Group C). 
The combined pattern is the most frequent 
histology in both genders and it seems to constitute 
an aggressive subtype that implies a higher risk 
of local relapse. This phenomenon allows us to 
suppose that the carcinogenesis progression 
in thyroid cells occurs simultaneously in several 
clones, as some authors have proposed (34). 
Another hypothesis is that other cell lines could 
derive from an initial clone.
We believe that the follicular variant is a derivation 
of the classic variant, which would be the first to 
appear in the majority of cases, either pure or 
combined. The follicular variant was more common 
in women, thus indicating that this behavior could 
be associated with hormonal factors, as has been 
reported in the literature (22,23). However, men 
present more aggressive phenotypes, as seen in 
the percentage of men with some risk variant or 
combined pattern which came to 45.58%; this 
concurs with previous studies on papillary thyroid 
carcinoma in Japan (11,35).
We did not observe a high frequency of microcarci-
nomas. This can be explained because Instituto 
Nacional de Cancerología is a reference center 
Table 2. Distribution of anatomo-pathological findings by sex and age
Associated factor
Sex Age
Women Men
Less than 18 
years of age
18 to 45 
years of age
Over 45 
years of age
n   (%) n   (%)  n (%)   n   (%) n   (%)
Size tumor
Carcinoma } >10 mm
Microcarcinoma  } <10 mm
Microtumor } <10 mm
Histologic variant
Combined pattern
Follicular
Classic
Tall cell
Solid
Macrofollicular
Oncocytic
Diffuse sclerosis
Clear cell
Columnar
Cribriform
Fasciitis-like
Squamous cell
Histological characteristics
Thyroid capsule invasion
Extrathyroid invasion
Lymph node metastasis
Extranodal metastasis
Lymphovascular invasion
Venous invasion
477   (87.4)
  39   (90.7)
  27   (90.0)
273   (87.8)
132   (91.0)
114   (83.2)
  10   (90.9)
 4 (100)
 2 (100)
 2 (100)
 2 (100)
 1 (100)
 1 (100)
 1 (100)
 1 (100)
 0     (0)
 
385   (88.3)
299   (83.2)
223   (83.2)
129   (81.1) 
  86   (79.6)
  68   (79.1)
 69   (12.6)
   4     (9.3)
   3   (10.0)
 38   (12.2)
 13     (9.0)
 23   (16.8)
   1     (9.1)
0     (0)
0     (0)
0     (0)
0     (0)
0     (0)
0     (0)
0     (0)
0     (0)
1 (100)
 51   (11.7)
 42   (12.3)
 45   (16.8)
 30   (18.9)
 22   (20.4)
 18   (20.9)
 
 10 (1.8)
   1 (2.3)
0 (0)
 
   7 (2.3)
   3 (2.1)
   1 (0.7)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
 
   9 (2.1)
   8 (2.3)
   7 (2.6)
   6 (3.8)
   3 (2.8)
   3 (3.5)
  192   (35.2)
    15   (34.9)
    12   (40.0)
  101   (32.5)
    41   (28.5)
    67   (48.9)
      2   (18.2)
   4 (100)
      1   (50.0)
   0     (0)
      1   (50.0)
   0     (0)
   0     (0)
   1 (100)
   1 (100)
   0     (0)
  144   (33.1)
  107   (31.5)
  111   (41.4)
    67   (42.1)
    45   (41.7)
    35   (40.7)
343   (62.9)
  27   (62.8)
  18   (60.0)
203   (65.3)
100   (69.4)
  69   (50.4)
    9   (81.8)
 0     (0)
 1   (50)
 2 (100)
 1   (50)
 1 (100)
 1 (100)
 0     (0)
 0     (0)
 1 (100)
282   (64.8)
225   (66.2)
150   (56.0)
  86   (54.1)
  60   (55.5)
  48   (55.8)
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mostly receiving already diagnosed patients for 
treatment. We seldom diagnose PTC in low risk 
population (36). In addition, Colombia does not 
have a widespread access to health services and 
many cancer patients are diagnosed and treated 
in later stages.
In our study, the combined pattern and follicular vari-
ant were the most frequent variants found in both 
carcinomas and microcarcinomas. A percentage of 
44.1% of microcarcinomas presented a combined 
pattern that developed metastases, and of these 
46.6% developed lymph node metastasis and 26.6 % 
extranodal metastasis. This allows us to propose 
that the combined pattern, regardless of tumor 
size, should be considered as a high risk variant 
(35,37,38). It should be pointed out that among 
both the predominant subtypes and the secondary 
subtypes high risk variants were present.
Out of the total number of microcarcinomas 
reported, only 25.58% presented multifocality 
and none presented relapse; these results are 
not very different from those reported by other 
authors who conclude that between 7% and 57% 
of microcarcinomas present multifocality. It has 
been considered that this feature is a strong factor 
in relapse occurrence (31-33,37).
The analysis performed among the principal histol-
ogical variants (classic, follicular and combined 
pattern) with tumoral histological characteristics 
revealed that the follicular variant had less 
probability of developing any type of invasion or 
metastasis; the opposite was true for the combined 
pattern, which showed a greater possibility of 
invasion or metastasis (table 3). 
A considerable percentage of patients (83.7%) 
presented no relapse; this percentage is inferior to 
that already reported (13). These results are limited 
due to the fact that this parameter was not evaluated 
in all cases. Of those patients who suffered relapse, 
the most common was loco-regional relapse, a 
fact which coincides with findings described in the 
literature (13). Nevertheless, metastasis in our study 
occurred with alarming frequency, which could be 
associated with various risk factors in our patients, 
such as the significant frequency of extrathyroidal 
invasion, large tumoral size and the presence of 
the combined pattern (table 3).
We reviewed clinical data of patients before PTC 
diagnosis and we tried to identify links between 
the combined pattern variant and benign thyroid 
conditions. Predominant benign or concomitant 
conditions were Hashimoto´s thyroiditis (33.9%) 
and goiter (33.1%) We did not find any significant 
relation between the combined pattern and these 
benign conditions (data not shown).
In conclusion, we propose including the combined 
pattern as a high risk variant, and we consider that 
more studies are needed in order to clarify the 
biological mechanism of variant development. Our 
study has limitations, including the relatively short, 
mean follow-up of our cohort and the retrospective 
nature of the review. Our results are similar to 
those previously reported in many aspects. The 
large size of the lesions and the high percentage 
of invasion maybe indicate that our patients were 
treated at later stages. It is probably different in 
other health institutions of the country where the 
microcarcinomas and small lesions are more 
frequent. These findings are important in order to 
establish health politicies in Colombia.
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Table 3. Frequencies and relative risk of major histological variants of papillary thyroid carcinoma and histological characteristics
Associated factor Classic papillary Follicular variant  Combined pattern
n  (%) RR (CI 95 %) p n  (%) RR (CI 95 %) p  n  (%) RR (CI 95 %) p
Thyroid capsule invasion
Lymphovascular invasion
Venous invasion
Extrathyroid invasion
Lymph node metastasis
Extranodal metastasis
62 (14.8)
20 (19.6)
17 (20.5)
46 (14.0)
55 (21.2)
30 (19.2)
0.77 (0.65-0.90)
0.79 (0.52-1.21)
0.87 (0.54-1.39)
0.67 (0.53-0.84)
1.08 (0.09-1.29)
0.97 (0.70-1.33)
0.0001
0.3477
0.6763
0.0001
0.4890
0.9732
89 (21.2)
14 (13.7)
12 (14.5)
63 (19.3)
38 (14.6)
19 (12.2)
0.80 (0.70-0.91)
0.47 (0.28-0.79)
0.52 (0.29-0.91)
0.72 (0.60-0.88)
0.64 (0.49-0.83)
0.53 (0.35-0.81)
0.0002
0.0026
0.0231
0.0003
0.0001
0.0018
 
 
 
 
 
 
268 (64.0)
  68 (66.7)
  54 (65.0)
218 (66.7)
167 (64.2)
107 (68.6)
1.34 (1.22-1.48)
1.71 (1.23-2.39)
1.68 (1.14-2.48)
1.54 (1.33-1.78)
1.24 (1.06-1.46)
1.54 (1.17-2.02)
0.0000
0.0016
0.0096
0.0000
0.0067
0.0016
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in papillary thyroid carcinomas from patients 
at the NCI, and description of the clinical and 
histopathologic features,” approved and funded 
by the Instituto Nacional de Cancerología.
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